J&J/Amgen Bundling Dispute Could Lead To Stricter CMS Accounting Rules
• By The Pink Sheet
Johnson & Johnson is moving on several fronts to counter Amgen pricing and discount policies it alleges are anti-competitive, and one result could be the Centers for Medicare & Medicaid Services (CMS) requiring more detailed discount reporting in the Medicare arena
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
